MedTrace Logo

Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells

NCT03554889 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2018-06-13

No results posted yet for this study

Summary

NK cells can persist and expand in vivo following adoptive transfer and may have a role in the treatment of late stage malignancies. NK also express an activating Fc receptor that mediates antibody-dependent cellular cytotoxicity (ADCC) and production of immune modulatory cytokines in response to antibody-coated targets. Nimotuzumab, an monoclonal antibody against EGFR (epidermal growth factor receptor), may enhance the ADCC effect of NK cell. This study will evaluate the safety of combination of nimotuzumab and NK Cell in treating advanced cancer patients. Blood samples will also be collected for research purposes.

Conditions

  • Advanced Cancer
  • ADCC
  • NK Cell Mediated Immunity
  • Nimotuzumab
  • Adaptive Transfer

Interventions

BIOLOGICAL

NK Cell adaptive transfer

Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer

DRUG

Nimotuzumab

Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer

Sponsors & Collaborators

  • Shanghai bokang bioengineering co., LTD

    collaborator UNKNOWN

  • Hangzhou Cancer Hospital

    lead OTHER

Principal Investigators

  • Shixiu Wu, Doctor · Hangzhou Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2019-03-30
Completion
2019-11-27

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03554889 on ClinicalTrials.gov